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Abstract
Background/Purpose
Radiation treatment (RT) stimulates the release of many immunohumoral factors, compli-
cating the identification of clinically significant cytokine expression patterns. This study used
principal component analysis (PCA) to analyze cytokines in non-small cell lung cancer
(NSCLC) patients undergoing RT and explore differences in changes after hypofractionated
stereotactic body radiation therapy (SBRT) and conventionally fractionated RT (CFRT) with-
out or with chemotherapy.
Methods
The dataset included 141 NSCLC patients treated on prospective clinical protocols; PCA
was based on the 128 patients who had complete CK values at baseline and during treat-
ment. Patients underwent SBRT (n = 16), CFRT (n = 18), or CFRT (n = 107) with concurrent
chemotherapy (ChRT). Levels of 30 cytokines were measured from prospectively collected
platelet-poor plasma samples at baseline, during RT, and after RT. PCA was used to study
variations in cytokine levels in patients at each time point.
Results
Median patient age was 66, and 22.7% of patients were female. PCA showed that sCD40l,
fractalkine/C3, IP10, VEGF, IL-1a, IL-10, and GMCSF were responsible for most variability
in baseline cytokine levels. During treatment, sCD40l, IP10, MIP-1b, fractalkine, IFN-r, and
VEGF accounted for most changes in cytokine levels. In SBRT patients, the most important
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Conclusions
PCA can identify potentially significant patterns of cytokine expression after fractionated RT.
Our PCA showed that inflammatory cytokines dominate post-treatment cytokine profiles,
and the changes differ after SBRT versus CFRT, with vs without chemotherapy. Further
studies are planned to validate these findings and determine the clinical significance of the
cytokine profiles identified by PCA.
Introduction
Although radiation therapy (RT) is primarily considered to be a local cancer treatment modal-
ity, it also induces a clinically significant systemic immune response. Circulating immuno-
modulatory factors known as cytokines are key modulators of the immune response to RT. It
is thought that RT-induced cytokine release is associated both with systemic inflammation and
augmentation of the immune response, as well as, paradoxically, with the development of
acute and long-term immunosuppression. Presently, however, the cytokine response to RT is
poorly understood. Gathering and analyzing data on cytokine expression in patients receiving
RT is complicated by several factors. Cytokine expression exhibits diurnal variations [1] and
changes in response to a variety of physiologic stressors including infection [2], cancer [3], and
trauma [4]. The presence of large interindividual differences in cytokine responses further
clouds the interpretation of cytokine expression patterns following radiation exposure [4].
Developing novel approaches to evaluating the complex cytokine response to RT is therefore
critical in attempting to improve our understanding of the immunomodulatory effects of RT
in cancer patients.
Prior analyses have identified certain (primarily inflammatory) individual cytokines as
responsive to RT in patients with NSCLC [5, 6]. To date, however, a comprehensive analysis of
cytokine expression patterns following RT has not been performed in lung cancer patients
undergoing radiation. To address this deficit, we conducted a prospective study with the goal
of collecting and analyzing a comprehensive panel of cytokines in NSCLC patients undergoing
definitive RT and to attempt to correlate cytokine expression patterns during treatment with
clinical outcomes. This study generated a complex dataset that includes levels of 30 different
cytokines sampled from over 100 patients. This paper is the first report of this large dataset
and will focus on changes in cytokine expression during RT.
Due to the complexity of the dataset, we used principal component analysis (PCA) to per-
form the data analysis. PCA, which transforms a large set of potentially inter-related variables
into a smaller and ideally more manageable dataset of composite variables,[7] is well suited to
performing exploratory analyses of complex data, and we selected this approach with the goal
of identifying potentially significant patterns of cytokine expression changes in NSCLC
patients undergoing radiation therapy while minimizing the risk of data loss.
Patterns of cytokine expression during radiotherapy for lung cancer
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Methods
Patients undergoing definitive RT for NSCLC under IRB-approved institutional prospective
protocols aimed at biomarker collection were eligible for this study, which enrolled 141
patients between March 2004 and April 2013. Written informed consent was obtained from
each participant prior to study entry. The study was approved by the internal institutional
review boards at each participating site (University of Michigan and Augusta University). All
clinical investigations were conducted in accordance with the principles of the Declaration of
Helsinki.
All patients were adults (at least 18 years of age); median age was 66 years. The majority of
patients were men (77.3%), had a history of cigarette smoking, and had locally advanced dis-
ease. However, due to present standards of care for the treatment of non-small cell lung cancer,
all patients in the SBRT group had earlier-stage (T1-T3, node negative) tumors. Further details
of the patients’ clinical and demographic characteristics are presented in Table 1. Written
informed consent was obtained from each participant prior to study entry. The first study was
a dose escalation study using iso-toxicity criteria; the second was a dose escalation protocol
using a PET-guided adaptive RT technique, with prescription dose limited by an iso-toxicity
criterion, similar to that described in the RTOG 1106 study. The dose varied from 63–85.5 Gy
in this protocol. In the second study, the radiation dose ranged from 66–90 Gy in 2.2- to
3.8-Gy fractions. The third study was an imaging and biomarker protocol using SBRT and
CFRT with or without chemotherapy. The radiation dose was typically given as 60–74 Gy in
2-Gy fractions for CFRT or 50, 55, or 60 Gy in 10-, 11-, or 20-Gy fractions for SBRT.
Blood samples were collected at baseline and mid-treatment for SBRT, two weeks after
starting CFRT. Samples were collected in K2EDTA-coated tubes for anticoagulation, placed
on ice immediately, and centrifuged at 3,000g for 30 minutes. The supernatant was stored at
-80˚C until analysis. A commercially available human cytokine/chemoking magnetic bead
panel kit (Milliplex1 MAP, Millipore, Billerica, MA, USA) was used to measure levels of the
following cytokines: 1) EGF; 2) eotaxin; 3) fractalkine/CX3CL1; 4) G-CSF; 5) GM-CSF; 6)
IFN-γ; 7) TGF-α; 8) TNF-α; 9) VEGF; 10) MCP-1; 11) IP-10/CXCL10; 12) MIP-1a; 13) MIP-
1b; 14) sCD40l; 15) IL-1a; 16) IL-1b; 17) IL-1r; 18) IL-2; 19) IL-4; 20) IL-5; 21) IL-6; 22) IL-7;
23) IL-8; 24) IL-10; 25) IL-12p40; 26) IL-12p70; 27) IL-13; 28) IL-15; and 29) IL-17. TGF-ß1
levels were analyzed separately using a dedicated ELISA kit (Human TGF-ß1 Duoset kit, R&D
Table 1. Basic clinical and demographic data.
SBRT ChRT CFRT
Age (years; median, range) 73 (63–84) 64 (32–68) 73 (40–85)
(n, %) Male 10 (62.5%) 81 (75.7%) 16 (88.9%)
(n, %) Female 6 (37.5%) 26 (24.3%) 2 (11.1%)
Tx 0 (0%) 1 (1%) 0 (0%)
T1 7 (47.0%) 14 (13.1%) 6 (33.3%)
T2 6 (33.3%) 25 (23.4%) 6 (33.3%)
T3 3 (20.0%) 36 (32.7%) 3 (16.7%)
T4 0 (0%) 31 (29.0%) 3 (16.7%)
N0 16 (100%) 19 (17.8%) 11 (61.1%)
N1 0 (0%) 10 (9.3%) 2 (11.1%)
N2 0 (0%) 47 (43.9%) 3 (16.7%)
N3 0 (0%) 30 (28.0%) 2 (11.1%)
Nx 0 (0%) 1 (1%) 0 (0%)
GTV size (cc; median, range) 33.1(4.4–206.6) 165.6 (2.1–921.0) 187.7 (2.4–802.6)
https://doi.org/10.1371/journal.pone.0183239.t001
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Systems, Inc., Minneapolis, MN, USA). All samples were tested in duplicate. PCA was used to
determine which cytokines explained the majority of the observed variations in cytokine levels
due to RT. The Kruskal-Wallis test was used to compare median cytokine levels among the
treatment groups.
Results
Study population
The present report includes results from 141 patients; PCA analysis was restricted to the 128
patients who had complete CK data at all prespecified time points of the analysis. Median age
was 66, and 22.7% of patients were women. The majority of patients in all groups were white
(124/128, 96%) and were either active smokers or had a history of cigarette smoking. Most
patients had excellent performance status and no significant differences in baseline perfor-
mance status were observed among the treatment groups (median baseline KPS in all three
groups was 90). In keeping with established practice standards, all of the SBRT patients had N0
disease, in comparison to 61.1% of the CFRT patients (11/18) and 28.0% of the ChRT patients
(30/107). Additionally, the treated volume was smaller in SBRT patients compared with the
CFRT and ChRT patients (mean 33.1 cm3 in SBRT patients vs 165.6 cm3 and 187.7 cm3 in the
CFRT and ChRt groups, respectively). Table 1 presents basic clinical and demographic data on
the patients included in this report.
PCA of cytokine levels in patients receiving RT
The following cytokines were identified by PCA as responsible for the bulk of the variations in
cytokine levels at baseline and during RT: fractalkine/CX3CL1, GM-CSF, IL-1a, IL-12 (p40),
IFN-γ, IP-10, MIP-1b, sCD40l, and VEGF. Fig 1 graphically shows the leading PCs identified
in our analysis. As shown in the figure, SBRT patients expressed a more limited repertoire of
cytokines and less variability in cytokine levels, both at baseline and during treatment, than
either the CFRT or ChRT patients. IP10 and sCD40l were identified as significant players in all
three groups both at baseline and during treatment. Otherwise, cytokine expression patterns
varied among the treatment groups, as shown in Fig 2a and 2b. Fractalkine/CX3CL1 appeared
to influence cytokine levels in SBRT and CFRT patients but not in the ChRT group, whereas
Fig 1. Graphical depiction of the PCA results at baseline and during RT. Group 1: SBRT; Group 2:
CFRT; Group 3: ChRT. RT = Radiation therapy, SBRT = Stereotactic body radiation therapy (SBRT),
CFRT = conventially fractionated radiation therapy, ChRT = Concurrent chemoradiation.
https://doi.org/10.1371/journal.pone.0183239.g001
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VEGF was identified as a potentially significant cytokine in SBRT and ChRT patients but not
CFRT patients. GM-CSF was also involved in cytokine expression patterns at baseline in non-
SBRT patients (i.e., CFRT and ChRT patients), whereas IL-12 was only identified as a poten-
tially significant factor at baseline in CFRT patients. The ChRT group appeared to be more
influenced by IFN-γ and IL-1a, whereas these cytokines did not appear to play as important a
role in the RT-alone groups (i.e., SBRT and CFRT patients).
PCA also identified specific cytokines as potentially major players in the response to RT.
For patients treated with SBRT, IP-10, MIP-1b, and sCD40l were responsible for the majority
of the variation in cytokine levels seen with treatment. In patients undergoing CFRT, fractalk-
ine/CX3CL1, IP-10, IL-12, GMCSF, and sCD40l appeared to be the most important cytokines;
and in ChRT patients, IP-10, MIP-1b, and sCD40l accounted for the majority of the variability
in cytokine levels during treatment, in addition to IFN-γ, IL-1a and VEGF. Interestingly, IL-1a
and IFN-γ were again identified as major players only in the ChRT patients. The reported PCs
accounted for 99.5% and 94.8% of the variability observed at baseline and during treatment,
respectively. We also analyzed changes in levels of the cytokines identified by PCA as poten-
tially key players among the three different treatment groups over time; these data are shown
in Table 2.
Discussion
The present study is the largest to date to prospectively collect and analyze a comprehensive
panel of cytokines in NSCLC patients undergoing definitive RT and to attempt to correlate
cytokine expression patterns with clinical outcomes. Our analysis demonstrates that PCA is a
potentially powerful tool for analyzing the complex patterns of cytokine release following RT
in patients with lung cancer and may provide additional information regarding potentially
clinically significant cytokines compared to an analysis of changes in median or mean levels
alone. PCA is a well-described statistical tool that can be used to analyze complex multidimen-
sional datasets and is frequently employed to identify hypothesis-generating patterns of inter-
est in the context of exploratory analyses such as the present study. [8] PCA is well suited to
the analysis of patterns of cytokine expression following radiation therapy, which is compli-
cated by several interrelated factors: 1) interindividual variability in RT-induced cytokine
Fig 2. Venn diagrams showing cytokine expression patterns at baseline in the three treated groups at
baseline (Fig 2a) and during RT (Fig 2b). SBRT = stereotactic body radiation therapy;
CFRT = conventionally fractionated radiation therapy; ChRT = concurrent chemoradiation therapy.
IL = interleukin; VEGF = vascular endothelial growth factor; GM-CSF = granulocyte-monocyte colony
stimulating factor; IFN = interferon.
https://doi.org/10.1371/journal.pone.0183239.g002
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Table 2. Median cytokine values at baseline and during treatment for cytokines identified as key players by PCA.
FRACTALKINE
CFRT ChRT SBRT P
Baseline (pre) 92.19 86.07 69.47 0.83
During (w2) 62.83 76.77 66.25 0.81
Δ (%) -31.8 -10.8 -4.6
GM-CSF
CFRT ChRT SBRT
Baseline (pre) 13.74 21.04 9.70 0.03
During (w2) 14.31 16.03 13.15 0.24
Δ (%) +4.1 -23.8 +35.6
IFN-γ
CFRT ChRT SBRT
Baseline (pre) 10.95 10.24 7.56 0.24
During (w2) 29.05 8.47 7.42 0.25
Δ (%) +165.2 -17.3 -1.9
IL-12p40
CFRT ChRT SBRT
Baseline (pre) 105.95 3.55 3.20 0.08
During (w2) 84.42 3.20 3.20 0.03
Δ (%) -20.3 -9.9 0
IL-1a
CFRT ChRT SBRT
Baseline (pre) 33.11 16.91 9.03 0.31
During (w2) 27.39 12.11 9.96 0.62
Δ (%) -17.3 -28.4 +10.3
IP-10
CFRT ChRT SBRT
Baseline (pre) 525.06 524.95 591.39 0.40
During (w2) 513.25 409/84 567.54 0.36
Δ (%) -2.2 -21.9 -4.0
MIP-1b
CFRT ChRT SBRT
Baseline (pre) 40.72 45.70 33.77 0.83
During (w2) 47.04 43.79 36.89 0.95
Δ (%) +15.5 -4.2 +9.2
sCD40l
CFRT ChRT SBRT
Baseline (pre) 380.08 493.08 277.75 0.15
During (w2) 368.58 406.26 300.09 0.37
Δ (%) -3.0 -17.6 +8.0
VEGF
CFRT ChRT SBRT
Baseline (pre) 82.57 78.06 71.78 0.97
During (w2) 67.21 69.91 64.26 0.89
Δ (%) -18.6 -10.4 -10.5
https://doi.org/10.1371/journal.pone.0183239.t002
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release; 2) the release of certain significant cytokines, such as TGF-β1, by tumors themselves;
3) variations in physical factors, such as radiation dose and the irradiated volume, that could
influence the timing and magnitude of cytokine release; and 4) the complex regulatory inter-
play among clinically significant cytokines that are released following RT. An additional
advantage of the use of PCA in the present study, which tested levels of 30 different cytokines
at multiple time points, is that this technique can reduce confounding due to multiple hypoth-
esis testing, a common pitfall when analyzing large and complicated datasets such as this.
Our work has identified fractalkine/CX3CL1, GM-CSF, IL-1a, IL-12 (p40), IFN-γ, IP-10,
MIP-1b, sCD40l, and VEGF as cytokines of possible clinical importance in NSCLC patients
who undergo RT. We also observed significant variability in cytokine expression patterns
among the different treatment groups both before and during RT. Interestingly, neither the
direction nor the magnitude of change in median cytokine level was consistently associated
with whether or not a particular cytokine had been identified by PCA as potentially significant,
suggesting that PCA may provide additional information beyond descriptive statistics (e.g.,
median and/or mean) in identifying cytokines of potential clinical importance.
The observed variations before RT may have been due to heterogeneity in baseline charac-
teristics of the patient population, such as age, differences in the tumor burden, or medical
comorbidities. Changes during RT may have resulted from a combination of tumor and nor-
mal tissue responses to treatment. SBRT patients demonstrated the least amount of variability
in cytokine expression at baseline and during RT, perhaps due to the fact that SBRT patients
had earlier-stage disease and underwent more conformal treatments. Additionally, these find-
ings may reflect differences in the inflammatory/immune response to the high-dose, short-
course RT administered to SBRT patients or differences in the timing of plasma collection rela-
tive to RT administration.
During RT, PCA showed that sCD40l and IP-10 were major players in all three treatment
groups, reflecting a primarily inflammatory picture which is consistent with previously
described effects of irradiation on the lung parenchyma [6, 9]. Soluble CD40 ligand (sCD40l)
is an 18-kDa protein that is primarily released by activated T cells and platelets. [10] It has
been primarily studied within the context of autoimmune diseases and cardiovascular pathol-
ogy; however, there is some evidence that it plays a role in malignant disease as well. [11] For
example, levels of this protein may be correlated with disease burden in patients with small cell
lung cancer and nasopharyngeal carcinoma. [12, 13] The CD40 receptor itself is involved in a
variety of immune and inflammatory responses, and ligand binding is associated with the
release of IL-6, IL-10, and IL-12. Interestingly, increased sCD40l levels may be associated
with an immunosuppressed phenotype, as ligand binding has been shown to stimulate both
myeloid and lymphoid suppressor cells as well as PD-1 expression in cancer patients. [14]
IP-10 (also known as CXCL10) and MIP-1β (also referred to as CCL4) are well established
pro-inflammatory cytokines. IP-10 has been shown to play a role in several autoimmune dis-
eases and is associated with the stimulation of an antiviral immune response in hepatitis C
infection. [15] Early increases in IP-10 have been associated with the risk of higher-grade pul-
monary toxicity in lung cancer patients treated with radiation therapy. [5] Limited clinical
data are available regarding the effects of MIP-1β in irradiated individuals, but it also appears
to be an immunostimulatory chemokine that directs leukocyte migration following tissue
injury. [16]
Fractalkine (or CX3CL1) is the only member of a unique subclass of chemokines that exists
in both a soluble and a membrane-bound form. Like the other cytokines consistently identified
as potentially important factors in our analysis, it is a pro-inflammatory molecule that is clini-
cally associated with vascular pathology as well as autoimmune diseases including rheumatoid
arthritis. Its role in malignancy is controversial, with some studies appearing to show that
Patterns of cytokine expression during radiotherapy for lung cancer
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fractalkine has antitumor activity, and other investigations suggesting that fractalkine may
play a pro-metastatic role in some settings. [17] Fractalkine levels have also been shown to cor-
relate with tumor burden in NSCLC. [18] It is interesting to note that this cytokine was identi-
fied as a major player by PCA at baseline in the SBRT and CFRT groups, but lost significance
during treatment in the SBRT patients, which may be suggestive of an early response to abla-
tive dose radiation therapy.
Additional cytokines of interest identified by the PCA include VEGF, GM-CSF, IL-12, IFN-
γ, and IL-1a. Although a detailed description of the potential role of each of these individual
substances in lung cancer is beyond the scope of this paper, each of these cytokines has been
identified in the past as either an inflammatory (VEGF, GM-CSF, IL-12, IFN-γ, IL-1a) or a
potentially antitumor (IL-12, IFNγ) cytokine. IL-8 and TGF-β have additionally been
identified by prior studies as clinically significant cytokines in NSCLC patients treated with
radiation. [9] Elevated TGF-β levels have been associated with a higher risk of radiation pneu-
monitis in several published series, as have low levels of IL-8. [19] It is unclear why neither IL-
8 nor TGF-β was identified by PCA as a potentially important player in the present analysis,
but one contributing factor may be the relatively low rate of grade 2 or greater pneumonitis
(approximately 20%) observed in our dataset, allowing tumor-related, rather than-toxicity-
related, effects to predominate.
Limitations of the present work include the fact that PCA can only be used to identify
potentially important contributors to the observed patterns of cytokine expression. PCA is
unable to provide detailed information regarding quantitative correlations between cytokine
levels and biologic/clinical outcomes of interest. Additionally, the number of SBRT patients
included in the dataset is relatively small, limiting our ability to draw definitive conclusions
from the data at hand. Furthermore, we are awaiting the results of additional analyses that cor-
relate levels of potentially clinically significant individual cytokines identified by PCA with
clinical outcomes including tumor control, patterns of failure, survival, and the development
of radiation-induced toxicity. Nevertheless, we believe that our analysis demonstrates the util-
ity of PCA as a statistical tool for parsing large and complex datasets such as the comprehen-
sive panel of cytokine expression analyzed herein and identifying candidates for more detailed
future analyses.
In conclusion, our analysis has demonstrated that PCA is a powerful statistical tool for ana-
lyzing cytokine expression profiles in patients undergoing RT. Despite the finding of a primar-
ily inflammatory cytokine profile in all patients during RT, cytokine expression patterns in
these patients vary significantly by treatment group, likely reflecting differences in tumor bur-
den as well as variations in the immune system’s response to alterations in target volume size,
daily radiation dose, and the use of chemotherapy. Based on the results of the PCA, further
studies are planned to determine whether cytokine expression patterns in NSCLC patients,
and specifically levels of the major players identified by PCA, are associated with other clinical
outcomes including high-grade toxicity, patterns of failure, and tumor control.
Supporting information
S1 Dataset. Complete clinical cytokine dataset. Anonymized clinical database on which this
report is based.
(PDF)
Author Contributions
Conceptualization: Bryan M. Rabatic, Martha Matuszak, Shruti Jolly.
Patterns of cytokine expression during radiotherapy for lung cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0183239 September 21, 2017 8 / 10
Data curation: Bryan M. Rabatic, Jie Chen, Weili Wang, Feng-Ming Kong.
Formal analysis: Jie Chen, Jeffrey Campbell, Martha Matuszak.
Funding acquisition: Feng-Ming Kong.
Investigation: Susannah G. Ellsworth, Bryan M. Rabatic, Jing Zhao, Paul Stanton, Martha
Matuszak, Shruti Jolly, Feng-Ming Kong.
Methodology: Jie Chen, Jeffrey Campbell, Feng-Ming Kong.
Project administration: Susannah G. Ellsworth, Jing Zhao, Paul Stanton, Shruti Jolly, Feng-
Ming Kong.
Resources: Paul Stanton, Martha Matuszak, Shruti Jolly, Feng-Ming Kong.
Supervision: Susannah G. Ellsworth, Bryan M. Rabatic, Feng-Ming Kong.
Validation: Weili Wang, Wenhu Pi, Shruti Jolly, Feng-Ming Kong.
Visualization: Bryan M. Rabatic, Jeffrey Campbell, Feng-Ming Kong.
Writing – original draft: Susannah G. Ellsworth, Bryan M. Rabatic, Jie Chen, Jing Zhao,
Shruti Jolly.
Writing – review & editing: Susannah G. Ellsworth, Bryan M. Rabatic, Jeffrey Campbell,
Wenhu Pi, Amy Miller, Feng-Ming Kong.
References
1. Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann
N Y Acad Sci. 2010 Apr; 1193:48–59. https://doi.org/10.1111/j.1749-6632.2009.05300.x PMID:
20398008
2. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013 Jan-Feb; 50(1):23–36. https://doi.org/10.
3109/10408363.2013.764490 PMID: 23480440
3. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013 May; 14
(6):e218–28. https://doi.org/10.1016/S1470-2045(12)70582-X PMID: 23639322
4. Easton R, Balogh ZJ. Peri-operative changes in serum immune markers after trauma: a systematic
review. Injury. 2014 Jun; 45(6):934–41. https://doi.org/10.1016/j.injury.2013.12.002 PMID: 24388280
5. Siva S, MacManus M, Kron T, Best N, Smith J, Lobachevsky P, et al. A pattern of early radiation-
induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell
lung cancer. PLoS One. 2014 Oct 7; 9(10):e109560. https://doi.org/10.1371/journal.pone.0109560
PMID: 25289758
6. Anscher MS, Kong FM, Jirtle RL. The relevance of transforming growth factor beta 1 in pulmonary injury
after radiation therapy. Lung Cancer. 1998 Feb; 19(2):109–20. PMID: 9567247
7. Sainani KL. Introduction to principal components analysis. PM R. 2014 Mar; 6(3):275–8. https://doi.org/
10.1016/j.pmrj.2014.02.001 PMID: 24565515
8. Siebert JC, Wagner BD, Juarez-Colunga E. Integrating and mining diverse data in human immunologi-
cal studies. Bioanalysis. 2014 Jan; 6(2):209–23. https://doi.org/10.4155/bio.13.309 PMID: 24423597
9. Kong FM, Wang S. Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol.
2015 Apr; 25(2):100–9. https://doi.org/10.1016/j.semradonc.2014.12.003 PMID: 25771414
10. Aloui C, Prigent A, Sut C, Tariket S, Hamzeh-Cognasse H, Pozzetto B, et al. The signaling role of CD40
ligand in platelet biology and in platelet component transfusion. Int J Mol Sci. 2014 Dec 3; 15
(12):22342–64. https://doi.org/10.3390/ijms151222342 PMID: 25479079
11. Ferroni P, Santilli F, Guadagni F, Basili S, Davi G. Contribution of platelet-derived CD40 ligand to inflam-
mation, thrombosis and neoangiogenesis. Curr Med Chem. 2007; 14(20):2170–80. PMID: 17691955
12. Caggiari L, Guidoboni M, Vaccher E, Barzan L, Franchin G, Gloghini A, et al. High serum levels of solu-
ble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical rele-
vance. Infect Agent Cancer. 2007 Mar 1; 2:5. https://doi.org/10.1186/1750-9378-2-5 PMID: 17331231
13. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, et al. Soluble CD40 ligand plasma levels in
lung cancer. Clin Cancer Res. 2004 Jan 15; 10(2):610–4. PMID: 14760083
Patterns of cytokine expression during radiotherapy for lung cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0183239 September 21, 2017 9 / 10
14. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al. Elevated serum soluble CD40
ligand in cancer patients may play an immunosuppressive role. Blood. 2012 Oct 11; 120(15):3030–8.
https://doi.org/10.1182/blood-2012-05-427799 PMID: 22932804
15. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand
(CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014 Mar; 13(3):272–80. https://doi.org/10.1016/
j.autrev.2013.10.010 PMID: 24189283
16. OMIM Entry 182284: Chemokine, CC Motif, Ligand 4 [Internet].; 2006 []. https://www.omim.org/entry/
182284.
17. Jones BA, Beamer M, Ahmed S. Fractalkine/CX3CL1: a potential new target for inflammatory diseases.
Mol Interv. 2010 Oct; 10(5):263–70. https://doi.org/10.1124/mi.10.5.3 PMID: 21045240
18. Mauri FA, Pinato DJ, Trivedi P, Sharma R, Shiner RJ. Isogeneic comparison of primary and metastatic
lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion. Oncol
Rep. 2012 Aug; 28(2):647–53. https://doi.org/10.3892/or.2012.1818 PMID: 22614623
19. Wang SL, Stenmark MH, Chen J, Lee J, Stanton P, Zhao J, et al. A novel radiation pneumonitis predic-
tive model with MLD and IL-8 for non-small cell lung cancer patients. International Journal of Radiation
Oncology Biology Physics. 2015; 93(S3):S153.
Patterns of cytokine expression during radiotherapy for lung cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0183239 September 21, 2017 10 / 10
